Cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz plus P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D): Analysis by age group

被引：0
|
作者：
Malik, Zafar
di Lorenzo, Giuseppe
Bracarda, Sergio
Ardavanis, Alexandros
Basaran, Mert
Parente, Phillip
de Schultz, Wito
Saad, Fred
van Oort, Inge
Gerritsen, Winald R.
Aparicio, Luis M. Anton
Matus, Geoffrey
Hitier, Simon
Heidenreich, Axel
Bahl, Amit
机构：
[1] Clatterbridge Canc Ctr, Bebington, England
[2] Univ Naples Federico II, GU Canc Sect, Naples, Italy
[3] Ist Toscano Tumori ITT, Osped San Donato USL8, Arezzo, Italy
[4] St Savas Anticanc Hosp, Athens, Greece
[5] Istanbul Univ, Inst Oncol, Istanbul, Turkey
[6] Monash Univ, Box Hill Hosp, Eastern Hlth Clin Sch, Melbourne, Vic 3004, Australia
[7] Asklepios Klin, Urol Klin, Weissenfels, Germany
[8] Univ Montreal, Ctr Hosp, CRCHUM, Montreal, PQ, Canada
[9] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands
[10] Hosp Juan Canalejo, Dept Oncol, La Coruna, Spain
[11] Ctr Hosp Chretien Liege, Clin St Joseph, Liege, Belgium
[12] Sanofi, Chilly Mazarin, France
[13] Univ Hosp Aachen, Aachen, Germany
[14] Univ Hosp Bristol NHS Fdn Trust, Bristol Haematol & Oncol Ctr, Bristol, Avon, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 04期
关键词：
D O I：
10.1200/jco.2014.32.4_suppl.109
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
109
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Interim safety analysis of a compassionate-use program (CUP) and early-access program (EAP) providing cabazitaxel (Cbz) plus prednisone (P) to patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel
    Malik, Zafar I.
    Di Lorenzo, Giuseppe
    Basaran, Mert
    Ardavanis, Alexandros
    Parente, Phillip
    de Schultz, Wito
    Saad, Fred
    van Oort, Inge
    Gerritsen, Winald R.
    Aparicio, Luis M. Anton
    Matus, Geoffrey
    Hitier, Simon
    Heidenreich, Axel
    Bahl, Amit
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] Updated safety results from a cohort compassionate-use programme (CUP) and early access programme (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz plus P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D)
    Malik, Z. I.
    Di Lorenzo, G.
    Ardavanis, A.
    Basaran, M.
    Parente, P.
    De Schultz, W.
    Saad, F.
    Van Oort, I.
    Hitier, S.
    Heidenreich, A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S697 - S697
  • [3] Cohort compassionate-use program and early access program with cabazitaxel plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: analysis by age group
    Malik, Z.
    Di Lorenzo, G.
    Bracarda, S.
    Ardavanis, A.
    Basaran, M.
    Parente, P.
    De Schultz, W.
    Saad, F.
    Van Oort, I.
    Gerritsen, W. R.
    Anton Aparicio, L. M.
    Matus, G.
    Hitier, S.
    Heidenreich, A.
    Bahl, A.
    BJU INTERNATIONAL, 2015, 115 : 61 - 62
  • [4] CABAZITAXEL (CBZ) plus PREDNISONE (P; CBZP) IN PATIENTS (PTS) WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PREVIOUSLY TREATED WITH DOCETAXEL (D): INTERIM RESULTS FROM COMPASSIONATE-USE PROGRAMME (CUP) AND EARLY-ACCESS PROGRAMME (EAP)
    Malik, Z. I.
    Di Lorenzo, G.
    Basaran, M.
    Parente, P.
    de Schultz, W.
    Gerritsen, W. R.
    Anton Aparicio, L. M.
    Hitier, S.
    Heidenreich, A.
    Bahl, A.
    ANNALS OF ONCOLOGY, 2012, 23 : 306 - 307
  • [5] REGIONAL ANALYSIS OF A COHORT COMPASSIONATE-USE PROGRAM AND EARLY ACCESS PROGRAM WITH CABAZITAXEL PLUS PREDNISONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PREVIOUSLY TREATED WITH DOCETAXEL
    Malik, Z.
    di Lorenzo, G.
    Bracarda, S.
    Ardavanis, A.
    Basaran, M.
    Parente, P.
    de Schultz, W.
    Saad, F.
    van Oort, I.
    Gerritsen, W. R.
    Aparicio, L. M. Anton
    Matus, G.
    Hitier, S.
    Heidenreich, A.
    Bahl, A.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 : 37 - 37
  • [6] CABAZITAXEL PLUS PREDNISONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (mCRPC) PREVIOUSLY TREATED WITH DOCETAXEL: ANALYSIS BY AGE GROUP
    Parente, P.
    Malik, Z.
    di Lorenzo, G.
    Bracarda, S.
    Ardavanis, A.
    Basaran, M.
    de Schultz, W.
    Saad, F.
    van Oort, I.
    Gerritsen, W. R.
    Anton Aparicio, L. M.
    Matus, G.
    Hitier, S.
    Heidenreich, A.
    Bahl, A.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 : 61 - 61
  • [7] PROSELICA study update: Comparison of two doses of cabazitaxel (Cbz) plus prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel (D)-containing regimen.
    Eisenberger, Mario A.
    Hardy-Bessard, Arnie Claire
    Ford, Daniel
    Mourey, Loic
    Parente, Phillip
    Mainwaring, Paul N.
    Ng, Siobhan
    Alekseev, Boris
    Matveev, Vsevolod
    Caries, Joan
    Shapiro, Jeremy
    Latorzett, Igor
    Bodrogi, Stvan
    Kim, Choung-Soo
    Font, Albert
    Segal, Roanne
    Van den Berg, Hendrik Pieter
    Zhang, Wenping
    Chadjaa, Mustapha
    De Bono, Johann Sebastian
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results.
    Bavbek, Sevil E.
    Malik, Zafar I.
    Di Lorenzo, Giuseppe
    Scholz, Hans-Jorg
    van Oort, Inge M.
    Siobhan Ng
    Ozguroglu, Mustafa
    Gerritsen, Winald R.
    Mueller, Stefan
    Marttila, Timo
    Aparicio, Luis M. Anton
    Albers, Peter
    Gschwend, Juergen E.
    Bensfia, Samira
    Ecstein-Fraisse, Evelyne B.
    Bracarda, Sergio
    Heidenreich, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results.
    Bavbek, Sevil E.
    Malik, Zafar
    Di Lorenzo, Giuseppe
    Scholz, Hans-Jorg
    van Oort, Inge M.
    Ng, Siobhan
    Ozguroglu, Mustafa
    Gerritsen, Winald R.
    Mueller, Stefan
    Marttila, Timo
    Anton-Aparicio, Luis M.
    Albers, Peter
    Gschwend, Juergen
    Bensfia, Samira
    Ecstein-Fraisse, Evelyne B.
    Bracarda, Sergio
    Heidenreich, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [10] CABAZITAXEL PLUS PREDNISONE (CBZP) IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL (D): EFFICACY AND SAFETY RESULTS FROM EARLY-ACCESS PROGRAM (EAP) SINGLE SITE EXPERIENCE
    Rescigno, P.
    D'Aniello, C.
    Federico, P.
    Puglia, L.
    Petremolo, A.
    Cavaliere, C.
    Buonerba, C.
    De Placido, S.
    Di Lorenzo, G.
    ANNALS OF ONCOLOGY, 2012, 23 : 316 - 317
12345